達安基因(002030.SZ):參股公司安傑思科創板IPO終止註冊
格隆匯9月13日丨達安基因(002030.SZ)公佈,近日,公司獲悉參股公司杭州安傑思醫學科技股份有限公司(簡稱“安傑思”)及其保薦機構中信證券於2021年9月3日分別提交了關於撤回安傑思首次公開發行股票並在科創板上市申請文件的申請。證監會於2021年9月8日下發了《中國證監會科創板股票發行註冊程序終止通知書》([2021]108號),根據《科創板首次公開發行股票註冊管理辦法(試行)》第三十一條的規定,決定終止對安傑思發行註冊程序。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.